rs1064608 — MTCH2 Pro290Ala

Missense variant in MTCH2 that reduces mitochondrial metabolic efficiency, increasing risk for obesity and sleep disruption through impaired energy substrate switching

See your personal result for MTCH2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

MTCH2 Pro290Ala — When Your Mitochondria Struggle to Choose Their Fuel

The mitochondria in your cells do not burn a fixed fuel. Depending on what you have eaten, your activity level, and the time of day, they switch between glucose and fatty acids — a flexibility that is central to healthy metabolism and, it turns out, to restorative sleep. MTCH2 (mitochondrial carrier homolog 211 mitochondrial carrier homolog 2
an outer mitochondrial membrane protein that regulates fuel switching and fusion dynamics) sits at this switching point. The Pro290Ala variant (rs1064608 C allele) subtly shifts how efficiently MTCH2 performs this role, with downstream effects on body weight, energy regulation, and sleep quality.

The Mechanism

MTCH2 is embedded in the outer mitochondrial membrane and performs two linked functions. First, it regulates carnitine palmitoyltransferase 1 (CPT1), the gate-keeping enzyme that determines how much fatty acid enters the mitochondrion for oxidation. When MTCH2 is functioning normally, it fine-tunes CPT1's sensitivity to malonyl-CoA — a metabolite that signals "enough fat is being burned, slow down." A functional change in MTCH2 shifts this gate, reducing fatty acid oxidation 22 Wu et al., MTCH2 modulates CPT1 activity to regulate lipid metabolism of adipocytes, Nat Commun 2025.

Second, MTCH2 promotes mitochondrial fusion during nutrient stress. When fuel is scarce, mitochondria normally elongate (hyperfuse) to extract more energy from available substrates. MTCH2 enables this response by coupling lipid synthesis flux to the fusion machinery via lysophosphatidic acid signaling 33 Labbé et al., MTCH2 links mitochondrial fusion to lipogenesis, J Cell Biol 2021. The Pro290Ala substitution changes a conserved proline in a transmembrane helix, likely affecting the protein's conformational flexibility and its interaction with CPT1 and fusion proteins.

The Evidence

The MTCH2 locus at chromosome 11 first emerged as a significant obesity signal in 2009, when Willer et al. conducted a GWAS in >91,000 individuals and identified six new BMI loci — TMEM18, KCTD15, GNPDA2, SH2B1, MTCH2, and NEGR144 when Willer et al. conducted a GWAS in >91,000 individuals and identified six new BMI loci — TMEM18, KCTD15, GNPDA2, SH2B1, MTCH2, and NEGR1
Willer CJ et al., Six new loci associated with body mass index, Nature Genetics 2009. MTCH2 was notable because the associated variants also implicated neuronal pathways, consistent with central regulation of energy balance.

In 2019, the largest insomnia GWAS to date — 1,331,010 individuals across multiple cohorts55 1,331,010 individuals across multiple cohorts
Jansen PR et al., Genome-wide analysis of insomnia, Nature Genetics 2019 — identified 202 loci enriched in genes expressed in hypothalamic and striatal neurons. The MTCH2 chromosomal region appeared among these loci, connecting the mitochondrial fuel-switching biology to the neuronal circuits that regulate sleep-wake transitions.

The functional mechanism was clarified by Fischer et al. 202366 Fischer et al. 2023
Fischer JA et al., Opposing effects of genetic variation in MTCH2 for obesity versus heart failure, Hum Mol Genet 2023, who showed that the Pro290 allele (G; the reference) associates with reduced MTCH2 expression via an eQTL (rs10838738), impaired glucose oxidation, and higher lactate production — but paradoxically lower BMI. The Ala290 allele (C), carried by about 35% of Europeans, is the higher-BMI genotype. Importantly, this study also identified a cardiac liability: reduced MTCH2 function (Pro290/lower expression) is overrepresented in cardiomyopathy cases, highlighting that the same gene variant has metabolically opposing effects depending on whether the tissue relies primarily on fatty acids (skeletal muscle, resting heart) or glucose (stressed heart).

The sleep connection is biologically coherent: hypothalamic neurons that control sleep-wake cycling depend on precise mitochondrial ATP production. When fuel switching is impaired, these neurons sustain suboptimal energy delivery during the early-morning hours when the body increases metabolic demand before waking — a window where mitochondrial efficiency is most critical for sleep consolidation.

Practical Actions

For carriers of one or two C alleles (Ala290), the actionable priority is supporting mitochondrial metabolic flexibility. Ubiquinol (the active form of CoQ10) directly supports the electron transport chain and has the strongest evidence for mitochondrial supplementation. Acetyl-L-carnitine supports CPT1-mediated fatty acid entry into mitochondria — a pathway MTCH2 variants specifically affect. Time-restricted eating windows of 8–10 hours help synchronize mitochondrial fuel cycling with circadian rhythms, reducing the metabolic load on MTCH2-dependent switching overnight.

For those with two C alleles, metabolic monitoring (fasting glucose, insulin, HbA1c) is warranted, given the documented link between MTCH2 impairment and glucose oxidation deficits.

Interactions

The MTCH2 locus shows genetic correlation with FTO (rs1421085, rs9939609), which independently affects fat mass and appetite regulation. Carrying risk alleles at both loci compounds adiposity risk beyond what either gene predicts alone — a compound action covering both genotypes would be appropriate if strong evidence of interaction exists. MTCH2 also sits in a pathway with PPARGC1A (PGC-1alpha), the master regulator of mitochondrial biogenesis; variants that reduce both MTCH2 function and PGC-1alpha expression may synergistically impair mitochondrial capacity.

Nutrient Interactions

coenzyme Q10 increased_need
carnitine increased_need

Genotype Interpretations

What each possible genotype means for this variant.

GG Efficient Fuel Switcher Normal

Standard mitochondrial fuel-switching efficiency

The GG genotype encodes two copies of proline at position 290, the ancestral residue in the MTCH2 transmembrane domain. MTCH2 at this position supports normal CPT1-mediated fatty acid oxidation, mitochondrial hyperfusion during caloric restriction, and standard glucose oxidation efficiency. Carriers of two G alleles show population-average BMI and no elevated metabolic disease risk attributable to this locus.

Note: The Fischer et al. 2023 data suggest the G allele paradoxically associates with slightly higher cardiac risk through a separate mechanism (impaired glucose oxidation in the failing heart), but this is a distinct phenotype from the metabolic-sleep phenotype relevant to this category.

CG Partial Metabolic Burden Intermediate

One copy of the Ala290 variant — moderately reduced mitochondrial metabolic flexibility

One copy of the Ala290 variant partially shifts MTCH2's interaction with CPT1, reducing fatty acid oxidation efficiency to an intermediate degree. The Willer 2009 GWAS confirmed additive effects of BMI-associated alleles at MTCH2, consistent with heterozygotes falling between the two homozygous phenotypes. Wu et al. 2025 showed MTCH2's role as a negative regulator of energy metabolism — intermediate loss of function modestly increases fat accumulation propensity. Sleep disruption at this genotype level is mild and often addressable through targeted supplementation and meal timing.

CC Reduced Mitochondrial Fuel Flexibility Reduced

Two copies of Ala290 — elevated metabolic burden and sleep disruption risk

Homozygosity for Ala290 maximally shifts the MTCH2 transmembrane domain, impairing its ability to regulate CPT1 sensitivity to malonyl-CoA and to facilitate mitochondrial hyperfusion during caloric restriction. Wu et al. 2025 demonstrated that MTCH2 ablation in adipocytes increases fatty acid accumulation rather than oxidation — the CC genotype recapitulates this phenotype to its greatest degree. Fischer et al. 2023 showed that MTCH2 impairment causes increased lactate production and reduced pyruvate dehydrogenase (PDH) activity, indicating a shift toward anaerobic glycolysis even when mitochondria should be performing aerobic oxidation.

Sleep quality is impaired because the same energy-switching deficit that promotes fat accumulation also limits ATP availability in sleep-regulatory neurons during the overnight fast. This is consistent with the identification of MTCH2-region variants in the 1.33-million-person insomnia GWAS, where loci enriched in hypothalamic neurons were specifically highlighted.

Importantly, this genotype also carries a separate cardiac consideration: the Jansen and Fischer data together suggest that while CC carriers have higher BMI burden, monitoring cardiac metabolic health is warranted, particularly under metabolic stress.